# PT-141 Research: Mechanism, Trials & Recent Studies (Bremelanotide) > PT-141 (bremelanotide) research: the central melanocortin mechanism, the RECONNECT Phase 3 trials, the 2022 fMRI study, and the most recent 2024–2026 literature — every figure cited. Mechanism, the two pivotal Phase 3 trials, the mechanistic neuroimaging, and the most recent literature — read as a cited ledger. ## The short version PT-141 research is unusually concrete because the compound is an FDA-approved drug with real human-trial data behind it. The core finding: bremelanotide works in the **brain**, not in blood flow. It activates **melanocortin receptors** (brain switches that, among other jobs, regulate sexual motivation) in the hypothalamus, and through that route it raises sexual desire [1][5]. The biggest studies are two matched Phase 3 trials in 1,267 women, which found a real but modest improvement in desire [3], plus a year-long follow-up that showed the effect held and that nausea was the main side effect [4]. A 2022 brain-imaging study showed the effect from inside the brain [5]. The sections below set out the mechanism, the key trials, and the most recent research, each finding cited to its source. ## Mechanism: a central melanocortin agonist PT-141 is a synthetic analogue of **alpha-MSH** (alpha-melanocyte-stimulating hormone — a natural signaling peptide cleaved from a precursor protein called POMC) [1]. It activates the melanocortin-4 receptor (MC4R) and, secondarily, MC3R — receptors concentrated in the hypothalamus and limbic system [1]. By stimulating MC4R in circuits such as the medial preoptic area (a hypothalamic region tied to sexual motivation), it is thought to engage dopamine pathways that govern desire and arousal [1]. This is the mechanistic dividing line from the older erectile-dysfunction drugs. A **PDE-5 inhibitor** acts peripherally on vascular smooth muscle to improve blood flow; PT-141 acts centrally, on the neural circuitry of sexual motivation [1]. Animal work supports the central account: systemic administration produced erections in rats and nonhuman primates and activated hypothalamic neurons (measured as increased c-Fos), and in male research it produced rapid dose-dependent erectile activity [1]. ## PT-141 peptide: structure and identity The **PT-141 peptide** is a cyclic heptapeptide lactam — a ring of seven amino acids closed by a bridge between two side chains — with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH [1]. Its molecular weight is 1025.2 Da, its formula is C50H68N14O10, and its CAS number is 189691-06-3 [1]. The cyclic ring confers greater stability than linear melanocortin peptides, which is part of why it became a viable drug [1]. Its international nonproprietary name is bremelanotide, and it reached the market under NDA 210557 in 2019 [7]. A 2020 analysis of FDA peptide and oligonucleotide approvals situates it within the strong 2019 cohort of peptide drug approvals [10]. ## PT-141 for women: the pivotal evidence The approval rests on the two RECONNECT Phase 3 trials, run as an identical pair in 1,267 premenopausal women with HSDD [3]. Bremelanotide 1.75 mg subcutaneous as-needed improved FSFI-desire by an integrated +0.35 (P<.001) and reduced FSDS-DAO desire distress by an integrated −0.33 (P<.001) versus placebo over 24 weeks; both coprimary endpoints were met in both trials [3]. The 52-week open-label extension in 684 women showed sustained efficacy and a stable safety profile [4]. The mechanism in women was imaged directly in 2022: in 31 premenopausal women with HSDD, MC4R agonism raised desire for up to 24 hours and altered task-based brain processing of erotic stimuli [5]. A review of female sexual-dysfunction treatment places bremelanotide specifically within the premenopausal-HSDD indication, distinct from off-label transdermal testosterone used in postmenopausal women [9]. ## PT-141 for men: investigational only Research in men exists, but it has not produced an approval. Early studies found rapid dose-dependent erectile activity in men with erectile dysfunction, consistent with the central mechanism [1]. In June 2024, the developer announced a Phase 2 study of roughly 50 patients testing bremelanotide co-administered with a PDE-5 inhibitor in men who do not respond to PDE-5-inhibitor monotherapy, with a co-formulation IND and a potential Phase 3 planned [8]. This program is **investigational**: it has not been reviewed or approved for marketing [8]. Any use of PT-141 in men today is off-label or research-grade, not an FDA-approved indication [7]. ## The most recent research The recent literature pulls in two directions, which is exactly why a balanced ledger is useful. On the supportive side, a 2026 systematic review and meta-analysis of female sexual-dysfunction treatments reported that bremelanotide improved total FSFI plus the desire and arousal subscales across pooled trials [13]. On the critical side, Spielmans (2024) argues the effects are small and questions the outcome interpretation [12]. Preclinical work continues to refine the mechanism. A 2025 study in female Syrian hamsters found MC3R/MC4R mRNA concentrated in dopamine neurons of the ventral tegmental area, but neither dose of bremelanotide changed melanocortin-receptor expression there, and the drug did not enhance sexual reward in a place-preference test — suggesting it does not act on the VTA reward circuit [6]. The honest reading: the central account holds, but the precise circuitry is still being mapped. --- An azure-ruled ledger of the PT-141 (bremelanotide) record — the 2019 approval, the 1,267-woman trials, and the half-life on the label entered as cited credits, with the small-effect critique, the ~40% nausea, and the premenopausal-HSDD-only boundary ruled in plain sight as the debits they are; no clinic balances behind this page and nothing here is dosed, prescribed, or sold.